Compare AbCellera Biologics Inc (ABCL) vs Conagra Brands Inc (CAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Conagra Brands Inc — how do they compare? AbCellera Biologics Inc trades at $11.64 (market cap $3.68B), while Conagra Brands Inc trades at $15.63 (market cap $7.73B). The key difference: Conagra Brands Inc is far larger — about 2.1× AbCellera Biologics Inc's market cap, and Conagra Brands Inc pays a 7.65% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CAG | |
|---|---|---|
Market Cap | $3.68B | $7.73B |
Sector | Health | Consumer Staples |
52-Week High | $12.50 | $20.02 |
52-Week Low | $2.78 | $12.58 |
Enterprise Value | $3.28B | $14.78B |
Dividend Yield | — | 7.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL trades at $11.36, up 0.71% today, with a bullish technical signal and strong analyst support. Recent Phase 2 trial success for ABCL635 drove a 33% intraday surge in August 2026, though the company reports negative net income margins and operating cash outflows. Revenue declined from $485M in 2022 to $75M in 2025, reflecting ongoing challenges in profitability despite clinical progress.
The stock offers upside to the $15.50 consensus price target but carries high risk due to persistent losses and cash burn. Investment appeal hinges on ABCL635's regulatory success and future revenue generation, while dilution from a $200M August 2026 offering and competitive pressures pose headwinds.
Conagra Brands (CAG) trades at $16.19, up 0.5% today, with a bullish technical signal from moving averages. Recent earnings show mixed results, with Q2 2026 beating estimates but Q1 2026 missing. The company reported 2025 revenue of $11.61B and net income of $1.15B, though 2026 projections indicate a net loss. A dividend of $0.18 is scheduled for payment in September 2026, following a 50% cut to improve financial flexibility amid margin pressures.
CAG presents a cautious outlook with low valuation metrics (P/E 10.06, P/S 0.68) offering downside support, but persistent sales declines and negative 2026 profit margins pose significant risks. Analyst consensus is mixed with 20.83% buy ratings, highlighting challenges in turnaround execution under new CEO John Brase. Investment opportunity hinges on successful cost management and brand investment, but weak growth and competitive pressures remain headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
